Last reviewed · How we verify
Fixed [Per/Ind/Aml]
A fixed-dose combination of perindopril (ACE inhibitor), indapamide (thiazide-like diuretic), and amlodipine (calcium channel blocker) that reduces blood pressure through multiple complementary pathways.
A fixed-dose combination of perindopril (ACE inhibitor), indapamide (thiazide-like diuretic), and amlodipine (calcium channel blocker) that reduces blood pressure through multiple complementary pathways. Used for Hypertension.
At a glance
| Generic name | Fixed [Per/Ind/Aml] |
|---|---|
| Sponsor | Institut de Recherches Internationales Servier |
| Drug class | ACE inhibitor / thiazide-like diuretic / calcium channel blocker combination |
| Target | ACE, sodium-potassium-ATPase, L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Perindopril inhibits angiotensin-converting enzyme to reduce angiotensin II-mediated vasoconstriction and aldosterone secretion. Indapamide acts as a thiazide-like diuretic promoting sodium and water excretion. Amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation. The combination provides synergistic antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
- Peripheral edema
- Hyperglycemia
- Hypokalemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fixed [Per/Ind/Aml] CI brief — competitive landscape report
- Fixed [Per/Ind/Aml] updates RSS · CI watch RSS
- Institut de Recherches Internationales Servier portfolio CI